Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly GLP1 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
GLP-1RAs have reliable hypoglycaemic and weight-loss effects that can intervene in obesitythe basis of type 2 diabetes pathologyand multifaceted effects on other cardiometabolic parameters, such as blood pressure and circulating lipids [21]
While these effects can vary from person to person and are still being studied, some patients experience positive changes that extend beyond appetite regulation
According to Harvard Health , low blood sugars are known to damage the hippocampusthe memory center of the brain. Additionally, diabetes is a risk factor for heart disease and high blood pressure, both of which can lead to stroke
Zepbound is a brand name for tirzepatide